| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Molecular Targets, and Chemical Biology |
vß6 Expression with Positron Emission Tomography1 Department of Biomedical Engineering, University of California Davis, Davis, California and 2 Centre for Tumour Biology, Barts and the London, Queen Mary's School of Medicine and Dentistry, London, United Kingdom
Requests for reprints: Julie L. Sutcliffe, Department of Biomedical Engineering, Genomics and Biomedical Sciences Facility, University of California Davis, 451 East Health Sciences Drive, Davis, CA 95616. Phone: 530-754-7107; Fax: 530-754-5739; E-mail: jlsutcliffe{at}ucdavis.edu and John F. Marshall, Centre for Tumour Biology, Institute of Cancer, Barts and the London, Queen Mary's School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, United Kingdom. E-mail: john.marshall{at}cancer.org.uk.
Expression of the epithelial-specific integrin
vß6 is low or undetectable in most adult tissues but may be increased during wound healing and inflammation and is up-regulated dramatically by many different carcinomas, making
vß6 a promising target for the in vivo detection of cancer using noninvasive imaging. In addition,
vß6 is recognized as promoting invasion and correlates with aggressive behavior of human cancers and thus agents that recognize
vß6 specifically in vivo will be an essential tool for the future management of
vß6-positive cancers. Recently, we identified the peptide NAVPNLRGDLQVLAQKVART (A20FMDV2), derived from foot-and-mouth disease virus, as a potent inhibitor of
vß6. Using flow cytometry and ELISA, we show that this peptide is highly selective, inhibiting
vß6-ligand binding with a IC50 of 3 nmol/L, an activity 1,000-fold more selective for
vß6 than for other RGD-directed integrins (
vß3,
vß5, and
5ß1). A20FMDV2 was radiolabeled on solid-phase using 4-[18F]fluorobenzoic acid, injected into mice bearing both
vß6-negative and
vß6-positive (DX3puro/DX3puroß6 cell lines) xenografts and imaged using a small animal positron emission tomography (PET) scanner. Rapid uptake (<30 min) and selective retention (>5 h) of radioactivity in the
vß6-positive versus the
vß6-negative tumor, together with fast renal elimination of nonspecifically bound activity, resulted in specific imaging of the
vß6-positive neoplasm. These data suggest that PET imaging of
vß6-positive tumors is feasible and will provide an important new tool for early detection and improved management of many types of cancers. [Cancer Res 2007;67(16):7833–40]
This article has been cited by other articles:
![]() |
M. K. J. Gagnon, S. H. Hausner, J. Marik, C. K. Abbey, J. F. Marshall, and J. L. Sutcliffe High-throughput in vivo screening of targeted molecular imaging agents PNAS, October 20, 2009; 106(42): 17904 - 17909. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Hausner, C. K. Abbey, R. J. Bold, M. K. Gagnon, J. Marik, J. F. Marshall, C. E. Stanecki, and J. L. Sutcliffe Targeted In vivo Imaging of Integrin {alpha}v{beta}6 with an Improved Radiotracer and Its Relevance in a Pancreatic Tumor Model Cancer Res., July 15, 2009; 69(14): 5843 - 5850. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Li, M. J. McGuire, M. Lin, Y.-H. Liu, T. Oyama, X. Sun, and K. C. Brown Synthesis and characterization of a high-affinity {alpha}v{beta}6-specific ligand for in vitro and in vivo applications Mol. Cancer Ther., May 1, 2009; 8(5): 1239 - 1249. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |